CMS’ proposal that patients be enrolled in a clinical trial or registry to get Medicare coverage for chimeric antigen receptor (CAR) T-cell therapies will help improve access, for the most part, but there is the risk that some organizations will choose not to offer this treatment, said John W. Sweetenham, MD, of Huntsman Cancer Institute at the University of Utah.
CMS’ proposal that patients be enrolled in a clinical trial or registry to get Medicare coverage for chimeric antigen receptor (CAR) T-cell therapies will help improve access, for the most part, but there is the risk that some organizations will choose not to offer this treatment, said John W. Sweetenham, MD, Huntsman Cancer Institute at the University of Utah.
Transcript
CMS recently proposed patients be enrolled in a clinical trial or registry to get Medicare coverage for CAR T-cell therapy. Do you think this will help or hinder improving access to these innovative therapies?
I think for the most part, it’s going to help. I think it will mean that, at least initially, I think that these treatments are going to remain under the management of established bone marrow transplant and cell therapy programs. And so, it will enable them to gain more expertise, which I think is important because there is a major learning curve still.
I think the potential downside, as pointed out by Sam Silver, MD, PhD, [of the University of Michigan Rogel Cancer Center] in the session [Thursday] morning was that with the current coverage determination, some organizations may simply choose not to offer this treatment to their Medicare population because there’s too much money at risk. So, that’s the potential downside.
But, overall, I think that the determination is good, the requirement for evidence is absolutely correct, because we really fully don’t understand the true impact of this treatment yet. So, I think in the sort of short- to medium-term this is a good decision.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More